Clinical trial Recruiting at 1 site Interventional Ages 60 to 90

Deep TMS to help thinking in older adults with mild cognitive decline

Official title: Feasibility and Tolerability of Deep Repetitive Transcranial Magnetic Stimulation for Mild Neurocognitive Disorder in Older Adults: A Pilot Study (DeepMIND)

Run by St. Joseph's Healthcare Hamilton · NCT07038798 · Data updated 2026-11-12

This pilot will try three types of deep transcranial magnetic stimulation (H1, H4, H7 coils) to see how tolerable they are and whether they affect thinking, mood, sleep, and brain activity in adults aged 60–90 with mild neurocognitive disorder.

Quick facts

Study typeInterventional
Ages60 Years to 90 Years
SexAll
Enrollment30 (estimated)
SponsorSt. Joseph's Healthcare Hamilton
Academic / other
Locations1 site (Hamilton, Ontario)
StatusRecruiting
StartedAugust 26, 2025
Main results expectedJanuary 2027
Study endsJanuary 2027
Registry record updatedOctober 6, 2025
Trial IDNCT07038798 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 60–90 with self-reported recent cognitive decline, objective mild impairment on testing, preserved independence in daily activities, and stable psychotropic medications are the intended participants.

Probably not a fit

People with severe depression, bipolar or psychotic disorders, significant neurological illness explaining their cognitive problems, impaired basic or instrumental activities of daily living, recent substance use disorders, or standard rTMS contraindications are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, parallel pilot assigns participants aged 60–90 to one of three dTMS H-coils (H1, H4, H7) and delivers a six-week course of 20 stimulation sessions. Feasibility and tolerability are measured with side-effect checklists and mental-health questionnaires, while cognition is measured with neuropsychological tests and CNS Vital Signs and brain activity is recorded with EEG at baseline, midpoint, end point, and follow-up. Self-report mood and sleep questionnaires are collected at the same timepoints to capture noncognitive effects. The trial will compare absolute and differential tolerability across coils to provide preliminary data for a future randomized sham-controlled trial.

Why it matters

Potential benefit: If successful, one of the coils could offer a tolerable, noninvasive option to improve or stabilize cognition, mood, or sleep in older adults with mild neurocognitive disorder.

How similar studies have gone: dTMS is FDA-approved for several psychiatric conditions and small studies have suggested possible cognitive benefits in Alzheimer's and other neurodegenerative disorders, but its use in mild NCD remains preliminary and not yet established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 60 - 90 years old
* Able to provide informed consent to participate in the study
* Subjective concern of mild decline in cognitive function over the past year
* Mild impairment in cognitive performance
* Preserved independence in everyday activities
* Independently mobile (e.g., participants must be able to get in and out of a chair on their own)
* Participants will be required to be on stable dosages of other psychotropic medications for at least 4 weeks prior to screening

Exclusion Criteria:

* Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder
* Active suicidal behavior
* Severe depression and/or anxiety
* Other neurological or psychiatric disorders accounting for the cognitive deficits
* Impairment in basic and/or instrumental activities of daily living
* Substance use disorder (other than tobacco use disorder) in the past 3 months before entering the study
* Traditional contraindications to rTMS: Intracranial or metal implants in the head or nearby regions, excluding the mouth, that cannot be safely removed; History of epilepsy or seizures; Active unstable medical condition (recent laboratory and neuroimaging alterations, delirium); Pacemaker and/or implantable cardioverter-defibrillators; current use of bupropion, treatment with equivalent benzodiazepine dose to lorazepam \>2 mg/day
* People with severe literacy, visual, or hearing issues that affect the ability to engage in the interviews
* People with recurring migraines or headaches (weekly or more)
* Frequent dizziness/vertigo
* Individuals residing beyond the borders of the Greater Hamilton Area and its neighbouring vicinities

Where it's running

  • Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton
    Hamilton, Ontario, Canada
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.